Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent

Archivum Immunologiae et Therapiae Experimentalis

Volumn 58, Issue 3, 2010, Pages 235-245

  Sochanik, Aleksander ^a   Mitrus, Iwona ^a   Smolarczyk, Ryszard ^a   Cichoń, Tomasz ^a   Śnietura, Mirosław ^a   Czaja, Maria ^b   Szala, Stanisław ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

^b UNIVERSITY OF SILESIA   (Poland)

Author keywords

Combined antitumor therapy; Doxorubicin; Pegylated liposomes; Vascular disruptive agents

Indexed keywords

ALANYLCYSTEINYLASPARTYLCYSTEINYLARGINYLGLYCYLASPARTYLCYSTEINYLPHENYLALANYLCYSTEINE DEXTRO[2 LYSYLLEUCYLALANYLLYSYLLEUCYLALANYLLYSINE]; CHOLESTEROL; DISTEAROYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; FOLATE RECEPTOR; LIPOSOME; MACROGOL; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TRANSPORT; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPOSOMAL DELIVERY; MELANOMA; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; REPEATED DRUG DOSE; SINGLE DRUG DOSE; TUMOR NECROSIS;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; CARRIER PROTEINS; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; DRUG THERAPY, COMBINATION; EPITHELIAL CELLS; FEMALE; HUMANS; INTEGRIN ALPHAVBETA3; LIPOSOMES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; RECEPTORS, CELL SURFACE;

EID: 77953020592     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-010-0077-y     Document Type: Article

References (43)

1. Abraham SA, Waterhouse DN, Mayer LD et al (2005) The liposomal formulation of doxorubicin. Methods Enzymol 391:71-97.
2. Allen TM (2002) Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2:750-763.
3. Arap W, Pasqualini R, Ruoslahti E (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279:377-380.
4. Banciu M, Schiffelers RM, Storm G (2008) Investigation into the role of tumor-associated macrophages in the antitumor activity of doxil. Pharm Res 25:1948-1955.
5. Bartlett GR (1959) Phosphorus assay in column chromatography. J Biol Chem 234:466-468.
6. Browder T, Butterfield CE, Kräling BM et al (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:878-1886.
7. Denekamp J (1984) Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol 23:217-225.
8. Denekamp J (1993) Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 66:181-196.
9. Dickson PV, Hamner JB, Sims TL et al (2007) Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13:3942-3950.
10. Eliaz RE, Szoka FC Jr (2001) Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res 61:2592-2601.
11. Ellerby HM, Arap W, Ellerby LM et al (1999) Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5:1032-1038.
12. Folkman J (1990) What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 82:4-6.
13. Folkman J (1996) New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 32A:2534-2539.
14. Gabizon A, Horowitz AT, Goren D et al (1999) Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies. Bioconjug Chem 10:289-298.
15. Gabizon A, Tzemach D, Mark L, Bronstein M, Horowitz AT (2002) Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J Drug Target 10:539-548.
16. Gabizon A, Isacson R, Rosengarten O et al (2008) An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemother Pharmacol 61:695-702.
17. Goren D, Horowitz AT, Tzemach D et al (2000) Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug- resistance efflux pump. Clin Cancer Res 6:1947-1957.
18. Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91-100.
19. Horsman MR, Siemann DW (2006) Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res 66:11520-11539.
20. Huwyler J, Drewe J, Krähenbühl S (2008) Tumor targeting using liposomal antineoplastic drugs. Int J Nanomedicine 3:21-29.
21. Kerbel RS (2000) Tumor angiogenesis: past, present and the new future. Carcinogenesis 21:505-515.
22. Kerbel RS (2001) Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J Clin Oncol 19(18 suppl):45S-49S.
23. Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727-739.
24. Lee RJ, Low PS (1994) Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem 269:3198-3204.
25. Lee RJ, Low PS (1995) Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta 1233:134-144.
26. Levine AM, Tulpule A, Espina B et al (2004) Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response. J Clin Oncol 22:2662-2670.
27. Lu WL, Qi XR, Zhang Q et al (2004) A pegylated liposomal platform: pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug. J Pharmacol Sci 95:381-389.
28. Ma J, Waxman DJ (2009) Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib. Clin Cancer Res 15:578-588.
29. Madden TD, Harrigan PR, Tai LC et al (1990) The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids 53:37-46.
30. Maeda H (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41:189-207.
31. Mitrus I, Delić K, Wróbel N et al (2006) Combination of IL-12 gene therapy and CTX chemotherapy inhibits growth of primary B16(F10) melanoma tumors in mice. Acta Biochim Pol 53:357-360.
32. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124.
33. Scappaticci FA (2002) Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 20:3906-3927.
34. Sharma US, Sharma A, Chau RI et al (1997) Liposome-mediated therapy of intracranial brain tumors in a rat model. Pharm Res 14:992-998.
35. Siemann DW, Rojiani AM (2005) The vascular disrupting agent ZD6126 shows increased tumor efficacy and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys 62:846-853.
36. Siemann DW, Chaplin DJ, Horsman MR (2004) Vascular-targeting therapies for treatment of malignant disease. Cancer 100:2491-2499.
37. 2 peptide in mouse B16(F10) melanoma model. Acta Biochim Pol 53:801-805.
38. Soloman R, Gabizon AA (2008) Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin. Clin Lymphoma Myeloma 8:21-32.
39. Szala S (2004) Two-domain vascular disruptive agents in cancer therapy. Curr Cancer Drug Targets 4:501-509.
40. Thorpe PE (2004) Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10:415-427.
41. Tozer GM, Kanthou C, Parkins C et al (2002) The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 83:21-38.
42. Verheul HM, Voest EE, Schlingemann RO (2004) Are tumours angiogenesis-dependent? J Pathol 202:5-13.
43. Zhou R, Mazurchuk R, Straubinger RM (2002) Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. Cancer Res 62:2561-2566.